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Polyarteritis nodosa (PAN) of the urinary tract is rare. An unusual case of systemic PAN involving the bladder neck is described. A 
27-year-old man, with known diastolic hypertension diagnosed 2 years earlier, was admitted with chronic urinary obstruction complicated 
by hydronephrosis. He had symptoms of myalgia and weight loss, was afebrile but had an elevated erythrocyte sedimentation rate and 
acute-on-chronic renal impairment. All virological and serological tests including hepatitis B and anti-neutrophil cytoplasmic antibody 
were negative. A computed tomography scan of the brain revealed small-vessel disease. A bladder neck mass was visualised on cystoscopy. 
Histological examination of this demonstrated a medium-sized necrotising vasculitis with small-vessel fibrinoid necrosis suggestive of 
PAN. At least six of the American College of Rheumatology criteria for PAN were met. The patient was treated with pulses of intravenous 
cyclophosphamide and oral corticosteroids with a good clinical response.
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Polyarteritis nodosa (PAN) was first described by Kussmaul and 
Maier[1] in 1866. The annual incidence is <1/million/year, while an 
incidence of 77/million/year has been recorded in hepatitis B virus 
(HBV)-endemic areas, with a male/female ratio of 2 - 3:1. [2] The 
Chapel Hill Consensus Conference in 1994 defined PAN as ‘necrotiz-
ing inflammation of medium sized or small arteries without glomeru-
lonephritis or vasculitis in arterioles, capillaries or venules’. [3] PAN can 
be primary or secondary to viral infection (e.g. HBV).[4] Antineutrophil 
cytoplasmic antibody (ANCA) testing is usually negative, which essen-
tially differentiates it from microscopic polyangiitis.[4] The disease often 
presents with vague and nonspecific signs and symptoms such as myal-
gia, arthralgia, fever, headaches, neuropathy and features of chronic 
kidney disease, and can manifest with symptoms of transient ischaemic 
attacks.[3] If left untreated, PAN is usually fatal as a result of progressive 
renal failure or gastrointestinal complications.[3]
The urological manifestations of PAN documented in the literature 
include ureteric stenosis and orchitis.[5,6] We present a case of systemic 
PAN involving the bladder in a man presenting with a bladder outlet 
obstruction due to a mass.
Case report
A 27-year-old man was admitted to a urology ward with chronic 
urinary obstruction and hydronephrosis diagnosed on an ultrasound 
scan. This was accompanied by severe myalgia, loss of weight 
(approximately 10 kg over 6 months) and suprapubic pain. His past 
history included only hypertension, diagnosed in 2010, which was 
never investigated for a possible secondary cause. 
He was afebrile and a complete physical examination was 
un remarkable. Diastolic blood pressure readings were noted to be 
consistently elevated (>90 mmHg).
Laboratory tests showed marked renal impairment (serum 
creatinine level 1 096 µmol/L), with a normocytic anaemia, an 
elevated erythrocyte sedimentation rate (105 mm/h) and an 
elevated C-reactive protein level of 65 mg/L. All virological and 
serological investigations, including HIV, hepatitis B surface antigen, 
hepatitis C virus antibodies, antinuclear antibodies, rheumatoid 
factor, a VDRL test, and perinuclear and cytoplasmic ANCA were 
negative. Complement levels (C3 and C4) were normal. Further 
investigations including a chest radiograph, electrocardiogram and 
echocardiogram were all normal.
A cystoscopy and bladder neck resection were carried out for the 
urinary outlet obstruction. Histological examination of a specimen 
from the bladder neck revealed medium-vessel vasculitis suggestive 
of PAN (Fig. 1). An uncontrasted brain computed tomography 
(CT) scan revealed age-inappropriate atrophy with multiple lacunar 
infarcts due to significant small-vessel disease. CT angiography was 
not performed, as contrast media could not be used because of the 
patient’s significantly impaired renal function.
The patient met 6 of the 10 American College of Rheumatology 
1990 criteria for the classification of PAN, including weight loss 
>4 kg, diffuse myalgia, diastolic BP >90 mmHg, elevated creatinine, 
appropriate histological findings and arteriographic abnormalities 
demonstrated on CT of the head.[7] The Birmingham Vasculitis 
Activity Score (BVAS) was calculated at 13.[8]
Oral prednisone (1 mg/kg) was commenced after excluding 
active and latent tuberculosis on sputum tests, chest radiography 
and Mantoux testing. Initial therapy with corticosteroids was, 
however, complicated by Klebsiella septicaemia, identified on 
blood culture and treated with appropriate antibiotics. On 
resolution of the sepsis, he was commenced on intravenous 
(IV) cyclophosphamide with mercaptoethane  sulphonate  Na 
(MESNA) according to the CYCLOPS protocol.[5] The dose 
of cyclophosphamide given was 10  mg/kg, reduced for renal 
function, every 2 weeks for 3 doses and then every 3 weeks for 
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3  doses. Oral prednisone was tapered after the first month by 
5 mg every 2 weeks down to a dose of 20 mg, then by 2.5 mg 
monthly to a dose of 10 mg.
The patient responded well to treatment. His renal function 
improved without requiring dialysis and the urinary outlet 
obstruction resolved. He was discharged with follow-up visits at 
the rheumatology, renal and urology outpatient clinics. At 6-month 
follow-up the serum creatinine level was down to 526 µmol/L and 
his BVAS score was 2.
Discussion
This case reflects an unusual presentation of systemic PAN diagnosed 
incidentally on bladder neck resection specimens. Testicular involve-
ment in systemic PAN is common, with a prevalence of up to 85%. [6] 
We identified an isolated study in the literature, evaluating the 
radiographic findings of abdominal PAN, where extrarenal PAN 
(urethral, bladder) was found in 2 of the 7 patients studied. [5] However, 
to our knowledge, PAN involving the urinary tract (especially the 
urethra and bladder neck) is not well described in the literature.
PAN is a potentially remitting disease with a lower relapse rate than 
granulomatosis with polyangiitis and microscopic polyangiitis. [3] 
The symptoms of PAN can be nonspecific in the early stages. A high 
index of suspicion is therefore required to achieve an early diagnosis 
and prompt treatment with immunosuppressive therapy. While the 
most common cause of renal impairment is related to vasculitis of 
the renal vessels, this case demonstrates the unusual possibility of a 
‘postrenal’ cause for renal failure in PAN.
The patient was treated successfully with pulses of IV cyclo-
phosphamide. Compared with oral cyclophosphamide, this regimen 
offers the potential advantage of a lower cumulative dose and the 
likelihood of lower rates of adverse effects.[5] Prolonged follow-up of 
the patient is needed to determine final outcomes.
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Fig. 1. (A) Sections of a medium-sized artery show luminal fibrin thrombi 
(white arrow). An adjacent small artery shows fibrinoid necrosis of the 
vessel wall (black arrowhead) (H&E, 100× magnification). (B) Sections of a 
medium-sized artery show transmural neutrophilic infiltrates and fibrinoid 
necrosis of the vessel wall (black arrows) (H&E, 400× magnification). 
(C)  Sections of a small artery show fibrinoid necrosis of the vessel wall 
(black arrowheads) (H&E, 400× magnification). (D) Histochemical stain 
highlights fibrin deposition and fibrinoid necrosis of the vessel wall (black 
arrow) (Martius Scarlet Blue, 400× magnification).
